Abstract
Chronic kidney disease (CKD) is a major healthcare burden that takes a toll on the quality of life of many patients. Emerging evidence indicates that a substantial proportion of these patients carry a genetic defect that contributes to their disease. Any effort to reduce the percentage of patients with a diagnosis of nephropathy heading towards kidney replacement therapies should therefore be encouraged. Besides early genetic screenings and registries, in vitro systems that mimic the complexity and pathophysiological aspects of the disease could advance the screening for targeted and personalized therapies. In this regard, the use of patient-derived cell lines, as well as the generation of disease-specific cell lines via gene editing and stem cell technologies, have significantly improved our understanding of the molecular mechanisms underlying inherited kidney diseases. Furthermore, organs-on-chip technology holds great potential as it can emulate tissue and organ functions that are not found in other, more simple, in vitro models. The personalized nature of the chips, together with physiologically relevant read-outs, provide new opportunities for patient-specific assessment, as well as personalized strategies for treatment. In this review, we summarize the major kidney-on-chip (KOC) configurations and present the most recent studies on the in vitro representation of genetic kidney diseases using KOC-driven strategies.
Original language | English |
---|---|
Pages (from-to) | 2985-2996 |
Number of pages | 12 |
Journal | Pediatric Nephrology |
Volume | 37 |
Issue number | 12 |
Early online date | 14 Mar 2022 |
DOIs | |
Publication status | Published - Dec 2022 |
Bibliographical note
Funding Information:This study has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska–Curie Grant agreement no. 813839 (JF), H2020 WIDESPREAD-05–2018-TWINNING Remodel (SMM; RM), the IMAGEN project which is co-funded by the PPP Allowance made available by Health ~ Holland, Top Sector Life Sciences & Health, to stimulate public–private partnerships (IMplementation of Advancements in GENetic Kidney Disease, LSHM20009; ESG, MJJ, RM) and Utrecht Institute for Pharmaceutical Sciences (MGV).
Publisher Copyright:
© 2022, The Author(s).
Keywords
- Gene editing
- Genetic kidney disorders
- In vitro models
- Kidney-on-chip
- Organ-on-chip